Enoticumab is an investigational, humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody developed as an anti-angiogenic therapy for solid tumors. It functions as a selective inhibitor of the Notch signaling pathway by specifically targeting the Delta-like ligand 4 (DLL4). By binding to DLL4, enoticumab blocks its interaction with the Notch receptors (primarily Notch1 and Notch4) on neighboring endothelial cells. This blockade inhibits the Notch signaling cascade, which is crucial for proper vascular development and tumor angiogenesis. In preclinical models, such as ovarian cancer xenografts, this mechanism has translated into significant anti-tumor activity and effective suppression of tumor growth.